Ferring Pharmaceuticals

Press Release

Enters Co-Promotion Agreement with Savient

Suffern, NY – July 19, 2005 – Ferring Pharmaceuticals Inc. announced today that it has entered into an agreement to market EUFLEXXA™, a novel, non-avian-derived biologic formulation of hyaluronic acid for the amelioration of knee pain due to osteoarthritis. This agreement forms part of a broader transaction whereby the Ferring Group acquired the global biologics manufacturing business of Savient Pharmaceuticals, Inc., including the worldwide rights to EUFLEXXA.

“This agreement represents an additional specialty marketing opportunity that expands our product line beyond infertility,” said Wayne Anderson, president of Ferring Pharmaceuticals. “It is in keeping with our corporate strategy of niche marketing specialty products with manageable physician prescribing audiences.”

EUFLEXXA is the first and only non-avian-derived biologic formulation of hyaluronic acid approved in the U.S. for osteoarthritis of the knee. Under the agreement, Ferring and Savient, the developers of the product, will jointly market EUFLEXXA, which is expected to launch in Q4 2005. Ferring will be forming a specialist field force for this purpose.

About Ferring Pharmaceuticals Inc.
Ferring Pharmaceuticals Inc., part of the Ferring Group, a privately owned, international pharmaceutical company, markets Menopur^® (menotropins for injection, USP), Bravelle^® (urofollitropin for injection, purified), Repronex^® (menotropins for injection, USP) and Novarel^® (chorionic gonadotropin for injection, USP) in the U.S. to infertility specialists and their patients. Ferring also offers the Q∙CAP™, the first and only needle-free reconstitution device, for use with its fertility treatments. The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology and infertility. For more information, visit www.ferringusa.com.

# # #